MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

Lundbeck

Status and phase: Completed; Phase 2

Conditions: Primary Insomnia

Treatments: Drug: Placebo / Duration of Treatment 3 Weeks; Drug: MK0928, gaboxadol / Duration of Treatment 3 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00266344

MK0928-040

2005_106

0928-040

Details and patient eligibility

About

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Sex: All

Ages: 20 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of primary insomnia

Exclusion criteria

• Patients with an active psychiatric disorder other than primary insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind